Carmot’s CT-996 GLP-1 candidate supports once-daily oral dosing for obesity and type 2 diabetesCarmot Therapeutics has revealed preliminary data from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for...
Tirzepatide found to reduce body weight regardless of duration of condition and BMI before treatment2 days ago